Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · IEX Real-Time Price · USD
18.11
-0.07 (-0.39%)
May 17, 2024, 4:00 PM EDT - Market closed
Edgewise Therapeutics Employees
Edgewise Therapeutics had 88 employees on December 31, 2023. The number of employees increased by 29 or 49.15% compared to the previous year.
Employees
88
Change (1Y)
29
Growth (1Y)
49.15%
Revenue / Employee
n/a
Profits / Employee
-$1,202,841
Market Cap
1.69B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88 | 29 | 49.15% |
Dec 31, 2022 | 59 | 28 | 90.32% |
Dec 31, 2021 | 31 | 12 | 63.16% |
Dec 31, 2020 | 19 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
U.S. Physical Therapy | 6,720 |
Tilray Brands | 1,600 |
Schrödinger | 867 |
Alphatec Holdings | 839 |
Arcus Biosciences | 577 |
Harmony Biosciences Holdings | 246 |
Kura Oncology | 142 |
Structure Therapeutics | 93 |
EWTX News
- 8 days ago - Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 - Business Wire
- 9 days ago - Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 11 days ago - Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors - Business Wire
- 12 days ago - Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
- 25 days ago - Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies - Business Wire
- 4 weeks ago - Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) - Business Wire
- 7 weeks ago - Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session - Business Wire
- 7 weeks ago - Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 - Business Wire